

To:

KUHARCHUK, TERRENCE N.  
FIELD ATKINSON PERRATON  
2000 Oxford Tower  
10235 - 101 Street  
Edmonton, Alberta  
T5J 3G1 Canada

**PCT**

**NOTIFICATION OF THE INTERNATIONAL  
APPLICATION NUMBER AND OF THE  
INTERNATIONAL FILING DATE**

(PCT Rule 20.5(c))

Date of mailing  
(day/month/year)

03 December 1999 (03.12.99)

Applicant's or agent's file reference  
42/33984-1**IMPORTANT NOTIFICATION**

International application No.

PCT/CA99/01123

International filing date (day/month/year)

22 November 1999 (22-11-99)

Priority date (day/month/year)

23 November 1998 (23-11-98)

Applicant: PULMONOX MEDICAL CORPORATION ET AL

Title of the invention: METHOD AND APPARATUS FOR TREATMENT OF RESPIRATORY  
INFECTIONS BY NITRIC OXIDE INHALATION

1. The applicant is hereby notified that the international application has been accorded the international application number and the international filing date indicated above.

2. The applicant is further notified that the record copy of the international application:

☒ [ X ] was transmitted to the International Bureau on 03 December 1999 (03.12.99)

☐ [ ] has not yet been transmitted to the International Bureau for the reason indicated below and a copy of this notification has been sent to the International Bureau\*:

☐ [ ] because the necessary national security clearance has not yet been obtained.

☐ [ ] because (reason to be specified):

\* The International Bureau monitors the transmittal of the record copy by the receiving Office and will notify the applicant (with Form PCT/IB/301) of its receipt. Should the record copy not have been received by the expiration of 14 months from the priority date, the International Bureau will notify the applicant (Rule 22.1(c)).

Name and mailing address of the Receiving Office  
Commissioner of Patents  
Canadian Receiving Office  
Box PCT, Ottawa/Hull K1A 0G9  
Facsimile No. (819) 953-9538

Authorized Officer:

*Chantal Hebert*  
Chantal Hebert (819) 997-6295

**States party to the Paris Convention for the Protection of Industrial Property  
and their two-letter codes (1 September 1999)**

Albania (AL)	Ecuador (EC)*	Lithuania (LT)	Slovakia (SK)
Algeria (DZ)	Egypt (EG)	Luxembourg (LU)	Slovenia (SI)
Argentina (AR)	El Salvador (SV)	Madagascar (MG)	South Africa (ZA)
Armenia (AM)	Equatorial Guinea (GQ)	Malawi (MW)	Spain (ES)
Australia (AU)	Estonia (EE)	Malaysia (MY)	Sri Lanka (LK)
Austria (AT)	Finland (FI)	Mali (ML)	Sudan (SD)
Azerbaijan (AZ)	France (FR)	Malta (MT)	Suriname (SR)
Bahamas (BS)	Gabon (GA)	Mauritania (MR)	Swaziland (SZ)
Bahrain (BH)	Gambia (GM)	Mauritius (MU)	Sweden (SE)
Bangladesh (BD)	Georgia (GE)	Mexico (MX)	Switzerland (CH)
Barbados (BB)	Germany (DE)	Monaco (MC)	Syrian Arab Republic (SY)
Belarus (BY)	Ghana (GH)	Mongolia (MN)	Tajikistan (TJ)
Belgium (BE)	Greece (GR)	Morocco (MA)	The former Yugoslav Republic of
Benin (BJ)	Grenada (GD)	Mozambique (MZ)	Macedonia (MK)
Bolivia (BO)	Guatemala (GT)	Netherlands (NL)	Togo (TG)
Bosnia and Herzegovina (BA)	Guinea (GN)	New Zealand (NZ)	Trinidad and Tobago (TT)
Botswana (BW)	Guinea-Bissau (GW)	Nicaragua (NI)	Tunisia (TN)
Brazil (BR)	Guyana (GY)	Niger (NE)	Turkey (TR)
Bulgaria (BG)	Haiti (HT)	Nigeria (NG)	Turkmenistan (TM)
Burkina Faso (BF)	Holy See (VA)	Norway (NO)	Uganda (UG)
Burundi (BI)	Honduras (HN)	Oman (OM)*	Ukraine (UA)
Cambodia (KH)	Hungary (HU)	Panama (PA)	United Arab Emirates (AE)
Cameroon (CM)	Iceland (IS)	Papua New Guinea (PG)*	United Kingdom (GB)
Canada (CA)	India (IN)*	Paraguay (PY)	United Republic of Tanzania (TZ)
Central African Republic (CF)	Indonesia (ID)	Peru (PE)	United States of America (US)
Chad (TD)	Iran (Islamic Republic of) (IR)	Philippines (PH)	Uruguay (UY)
Chile (CL)	Iraq (IQ)	Poland (PL)	Uzbekistan (UZ)
China (CN)	Ireland (IE)	Portugal (PT)	Venezuela (VE)
Colombia (CO)	Israel (IL)	Republic of Korea (KR)	Viet Nam (VN)
Congo (CG)	Italy (IT)	Republic of Moldova (MD)	Yugoslavia (YU)
Costa Rica (CR)	Japan (JP)	Romania (RO)	Zambia (ZM)
Côte d'Ivoire (CI)	Jordan (JO)	Russian Federation (RU)	Zimbabwe (ZW)
Croatia (HR)	Kazakhstan (KZ)	Rwanda (RW)	
Cuba (CU)	Kenya (KE)	Saint Kitts and Nevis (KN)	
Cyprus (CY)	Kyrgyzstan (KG)	Saint Lucia (LC)	
Czech Republic (CZ)	Lao People's Democratic Republic (LA)	Saint Vincent and the Grenadines (VC)	
Democratic People's Republic of Korea (KP)	Latvia (LV)	San Marino (SM)	
Democratic Republic of the Congo (CD)	Lebanon (LB)	Sao Tome and Principe (ST)	
Denmark (DK)	Lesotho (LS)	Senegal (SN)	
Dominica (DM)*	Liberia (LR)	Sierra Leone (SL)	
Dominican Republic (DO)	Libyan Arab Jamahiriya (LY)	Singapore (SG)	(Total: 155 States)
	Liechtenstein (LI)		

## PCT REQUEST

Original (for SUBMISSION) - printed on 22.11.1999 12:53:45 PM


0 0-1	For receiving Office use only International Application No.	PCT/CA 99/01123
0-2	International Filing Date	22 Nov 1999 (22.11.99)
0-3	Name of receiving Office and "PCT International Application"	
0-4 0-4-1	Form - PCT/RO/101 PCT Request Prepared using	PCT-EASY Version 2.90 (updated 15.10.1999)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	Canadian Patent Office (RO/CA)
0-7	Applicant's or agent's file reference	42/33984-1
I	Title of invention	METHOD AND APPARATUS FOR TREATMENT OF RESPIRATORY INFECTIONS BY NITRIC OXIDE INHALATION
II II-1 II-2 II-4 II-5	Applicant This person is: Applicant for Name Address	applicant only all designated States except US PULMONOX MEDICAL CORPORATION 5243 - 53 Avenue Tofield, Alberta T0B 4J0 Canada
II-6	State of nationality	CA
II-7	State of residence	CA
II-8	Telephone No.	1-780-451-2626
II-9	Facsimile No.	1-780-451-2627
III-1 III-1-1 III-1-2 III-1-4 III-1-5	Applicant and/or inventor This person is: Applicant for Name (LAST, First) Address	applicant and inventor US only MILLER, Chris, C. 4231 Glenhaven Crescent North Vancouver, British Columbia V7G 1B8 Canada
III-1-6	State of nationality	CA
III-1-7	State of residence	CA

IV-1	Agent or common representative, or address for correspondence. The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	KUHARCHUK, Terrence, N.
IV-1-2	Address:	FIELD ATKINSON PERRATON 2000 Oxford Tower 10235 - 101 Street Edmonton, Alberta T5J 3G1 Canada
IV-1-3	Telephone No.	1-780-423-7646
IV-1-4	Facsimile No.	1-780-428-9329
IV-1-5	e-mail	tkuharchuk@fielddlaw.com
IV-2	Additional agent(s)	agent
IV-2-1	Name (LAST, First)	GARWASIUK, Helen
IV-2-2	Address:	2000 Oxford Tower 10235 - 101 Street Edmonton, Alberta T5J 3G1 Canada
IV-2-3	Telephone No.	1-780-423-7629
IV-2-4	Facsimile No.	1-780-428-9329
IV-2-5	e-mail	hgarwasiuk@fielddlaw.com
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW SD SL SZ TZ UG ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AL AM AT AU AZ BA BB BG BR BY CA CH&LI CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG

## PCT REQUEST

42/33984-1

Original (for SUBMISSION) - printed on 22.11.1999 12:53:45 PM

V-5	<b>Precautionary Designation Statement</b> In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	<b>Exclusion(s) from precautionary designations</b>	NONE
VI-1	<b>Priority claim of earlier national application</b>	
VI-1-1	Filing date	23 November 1998 (23.11.1998)
VI-1-2	Number	2,254,545
VI-1-3	Country	CA
VI-2	<b>Priority document request</b> The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s):	VI-1
VII-1	<b>International Searching Authority Chosen</b>	European Patent Office (EPO) (ISA/EP)
VIII	<b>Check list</b>	number of sheets
VIII-1	Request	4
VIII-2	Description	19
VIII-3	Claims	7
VIII-4	Abstract	1
VIII-5	Drawings	6
VIII-7	TOTAL	37
VIII-8	<b>Accompanying items</b>	paper document(s) attached
VIII-8	Fee calculation sheet	✓
VIII-16	PCT-EASY diskette	-
VIII-18	Figure of the drawings which should accompany the abstract	1
VIII-19	<b>Language of filing of the international application</b>	English
IX-1	<b>Signature of applicant or agent</b>	
IX-1-1	Name (LAST, First)	KUHARCHUK, Terrence, N.

## FOR RECEIVING OFFICE USE ONLY

10-1	<b>Date of actual receipt of the purported international application</b>	
------	--	--

## PCT REQUEST

42/33984-1

Original (for SUBMISSION) - printed on 22.11.1999 12:53:45 PM

10-2	Drawings:	
10-2-1	Received ✓	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported International application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

## FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

METHOD AND APPARATUS FOR TREATMENT OF RESPIRATORY  
INFECTIONS BY NITRIC OXIDE INHALATION

FIELD OF THE INVENTION

5

The present invention relates to a method for suppressing pathogenic cells, as well as a method for the treatment of an animal, including a human, having pathogenic cells within its respiratory tract. These methods preferably comprise the exposure of the pathogenic cells to an effective amount of a source of nitric oxide, the  
10 nitric oxide source comprising nitric oxide or a compound or substance capable of producing nitric oxide and wherein the nitric oxide may have either an inhibitory or a cidal effect on such pathogenic cells.

Further, the present invention relates to the use of nitric oxide for  
15 suppressing pathogenic cells, the therapeutic use of nitric oxide for the treatment of an animal having pathogenic cells in its respiratory tract and a pharmaceutical composition for such treatment.

As well, in a preferred embodiment, the present invention relates to the  
20 use of nitric oxide in a gaseous form (NO) in the treatment of fungal, parasitic and bacterial infections, particularly pulmonary infection by mycobacterium tuberculosis. The invention also relates to an improved apparatus or device for the delivery, particularly pulsed-dose delivery, of an effective amount of nitric oxide for the treatment of microbial based diseases which are susceptible to nitric oxide gas. The device  
25 preferably provides nitric oxide replacement therapy at a desired dose for infected respiratory tract infections, or provides nitric oxide as a sterilizing agent for medical and other equipment, instruments and devices requiring sterilization.

BACKGROUND OF THE INVENTION

30

In healthy humans, endogenously synthesized nitric oxide (NO) is thought to exert an important mycobacteriocidal or inhibitory action in addition to a vasodilatory action. There have been a number of ongoing, controlled studies to ascertain the benefits, safety and efficacy of inhaled nitric oxide as a pulmonary vasodilator. Inhaled nitric

oxide has been successfully utilized in the treatment of various pulmonary diseases such as persistent pulmonary hypertension in newborns and adult respiratory distress syndrome. There has been no attempt, however, to reproduce the microbacteriocidal or inhibitory action of NO with exogenous NO.

5

Further background information relating to the present invention may be found in the following references:

1. Lowenstein, C.J., J.L. Dinerman, and S.H. Snyder. 1994. Nitric oxide: a  
10 physiologic messenger" *Ann. Intern. Med.* 120:227-237.
2. The neonatal inhaled nitric oxide study group. 1997. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. *N. Engl. J. Med.* 336:597-604.
3. Roberts, J.D. Jr., J.R. Fineman, F.C. Morin III, et al. for the inhaled nitric oxide  
15 study group. 1997. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. *N. Engl. J. Med.* 336:605-610.
4. Rossaint, R., K.J. Falke, F. Lopez, K. Slama, U. Pison, and W.M. Zapol. 1993. Inhaled nitric oxide for the adult respiratory distress syndrome. *N. Engl. J. Med.* 328:399-405.
- 20 5. Rook, G.A.W. 1997. Intractable mycobacterial infections associated with genetic defects in the receptor for interferon gamma: what does this tell us about immunity to mycobacteria? *Thorax.* 52 (Suppl 3):S41-S46.
6. Denis, M. 1991. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. *Cell. Immunol.* 132:150-157.  
25
7. Chan, J., R. Xing, R.S. Magliozzo, and B.R. Bloom. 1992. Killing of virulent *Mycobacterium tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. *J. Exp. Med.* 175:1111-1122.
8. Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B.R. Bloom. 1995. Effects of nitric  
30 oxide synthase inhibitors on murine infection with *Mycobacterium tuberculosis*. *Infect. Immun.* 63:736-740.
9. Nozaki, Y., Y. Hasegawa, S. Ichiyama, I. Nakashima, and K. Shimokata. 1997. Mechanism of nitric oxide - dependent killing of *Mycobacterium bovis* BCG in human alveolar macrophages. *Infect. Immun.* 65:3644-3647.



10. Canetti, G. 1965. Present aspects of bacterial resistance in tuberculosis. *Am. Rev. Respir. Dis.* 92:687-703.
11. Hendrickson, D.A., and M.M. Krenz. 1991. Regents and stains, P. 1289-1314. In Balows, A, W.J. Hausler Jr., K.L. Herrmann, H.D. Isenberg, and I-li. Shadomy (eds.), *Manual of Clinical Microbiology*, 5th ed., 1991. American Society for Microbiology, Washington, D.C.
12. Szabo, C. 1996. The pathophysiological role of peroxynitrite in shock, inflammation and ischemia - reperfusion injury. *Shock*. 6:79-88.
13. Stavert, D.M., and B.E. Lehnert. 1990. Nitrogen oxide and nitrogen dioxide as inducers of acute pulmonary injury when inhaled at relatively high concentrations for brief periods. *Inhal. Toxicol.* 2:53-67.
14. Hugod, C. 1979. Effect of exposure to 43 PPM nitric oxide and 3.6 PPM nitrogen dioxide on rabbit lung. *mt. Arch. Occup. Environ. Health.* 42:159-167
15. Frostell, C., M.D. Fratacci, J.C. Wain, R. Jones and W.M. Zapol. 1991. Inhaled nitric oxide, a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. *Circulation.* 83:2038-2047.
16. BuIt, H., G.R.Y. De Meyer, F.H. Jordaens, and A.G. Herman. 1991. Chronic exposure to exogenous nitric oxide may suppress its endogenous release and efficacy. *J. Cardiovasc. Pharmacol.* 17:S79-S82.
17. Buga, G.M., J.M. Griscavage, N.E. Rogers, and L.J. Ignarro. 1993. Negative feedback regulation of endothelial cell function by nitric oxide. *Circ. Res.* 73:808-812
18. Assreuy, J., F.Q. Cunha, F.Y. Liew, and S. Moncada. 1993. Feedback inhibition of nitric oxide synthase activity by nitric oxide. *Br. J. Pharmacol.* 108:833-837.
19. O'Brien, L., J. Carmichael, D.B. Lowrie and P.W. Andrew. 1994. Strains of *Mycobacterium tuberculosis* differ in susceptibility to reactive nitrogen intermediates in vitro. *Infect. Immun.* 62:5187-5190.
20. Long, R., B. Maycher, A. Dhar, J. Manfreda, E. Hershfield, and N.R. Anthonisen. 1998. Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function. *Chest.* 113:933-943.
21. Bass, H., J.A.M. Henderson, T. Heckscher, A. Oriol, and N.R. Anthonisen. 1968. Regional structure and function in bronchiectasis. *Am. Rev. Respir. Dis.* 97:598-609.

## SUMMARY OF THE INVENTION

In a first aspect of the invention, the invention relates to a method for suppressing pathogenic cells, and a method for treating an animal having pathogenic cells in its respiratory tract, utilizing a source of nitric oxide. More particularly, in the first aspect of this invention, the invention relates to a method for suppressing pathogenic cells comprising the step of exposing the pathogenic cells to an effective amount of a nitric oxide source. Further, the invention relates to a method for treating an animal having pathogenic cells in the respiratory tract of the animal comprising the step of delivering by the inhalation route to the respiratory tract of the animal an effective amount of a nitric oxide source.

In a second aspect of the invention, the invention relates to a use and a therapeutic use of a source of nitric oxide for suppressing or treating pathogenic cells. More particularly, in the second aspect of the invention, the invention relates to the use of an effective amount of a nitric oxide source for suppressing pathogenic cells exposed thereto. Further, the invention relates to the therapeutic use of an effective amount of a nitric oxide source for the treatment by the inhalation route of an animal having pathogenic cells in the respiratory tract of the animal. Preferably, as discussed further below, the present invention relates to the novel use of inhaled nitric oxide gas as an agent for killing bacterial cells, parasites and fungi in the treatment of respiratory infections.

In a third aspect of the invention, the invention relates to a pharmaceutical composition for use in treating an animal having pathogenic cells in its respiratory tract, which composition comprises a nitric oxide source. More particularly, in the third aspect of the invention, the invention relates to a pharmaceutical composition for use in the treatment by the inhalation route of an animal having pathogenic cells in the respiratory tract of the animal, the pharmaceutical composition comprising an effective amount of a nitric oxide source.

Finally, in a fourth aspect of the invention, the invention relates to an apparatus or device for supplying, delivering or otherwise providing a nitric oxide source. Preferably, the apparatus or device provides the nitric oxide source for the

particular applications, methods and uses described herein. However, the apparatus or device may also be used for any application, method or use requiring the supply, delivery or provision of a nitric oxide source.

5                   In all aspects of the invention, the nitric oxide source is preferably nitric oxide *per se*, and more particularly, nitric oxide gas. However, alternately, the nitric oxide source may be any nitric oxide producing compound, composition or substance. In other words, the nitric oxide source may be any compound, composition or substance capable of producing or providing nitric oxide, and particularly, nitric oxide gas. For  
10 instance, the compound, composition or substance may undergo a thermal, chemical, ultrasonic, electrochemical or other reaction, or a combination of such reactions, to produce or provide nitric oxide to which the pathogenic cells are exposed. As well, the compound, composition or substance may be metabolized within the animal being treated to produce or provide nitric oxide within the respiratory tract of the animal.

15                   Further, in all aspects of the invention, the invention is for use in suppressing or treating any pathogenic cells. For instance, the pathogenic cells may be tumor or cancer cells. However, the pathogenic cells are preferably pathogenic microorganisms, including but not limited to pathogenic bacteria, pathogenic parasites  
20 and pathogenic fungi. More preferably, the pathogenic microorganisms are pathogenic mycobacteria. In the preferred embodiment, the pathogenic mycobacteria is *M. tuberculosis*.

                  Referring to the use of the nitric oxide source and method for suppressing  
25 pathogenic cells using the nitric oxide source, as indicated, the nitric oxide source is preferably nitric oxide *per se*. However, the nitric oxide source may be a compound, composition or substance producing nitric oxide. In either event, the pathogenic cells are suppressed by the nitric oxide. Suppression of the pathogenic cells by nitric oxide may result in either or both of an inhibitory effect on the cells and a cidal effect on the cells.  
30 However, preferably, the nitric oxide has a cidal effect on the pathogenic cells exposed thereto. Thus, it has been found that these aspects of the invention have particular application for the sterilization of medical and other equipment, instruments and devices requiring sterilization.

As well, the pathogenic cells may be exposed to the nitric oxide and the exposing step of the method may be performed in any manner and by any mechanism, device or process for exposing the pathogenic cells to the nitric oxide source, and thus nitric oxide, either directly or indirectly. However, in the preferred embodiment, the pathogenic cells are directly exposed to the nitric oxide. As a result, where desired, the effect of the nitric oxide may be localized to those pathogenic cells which are directly exposed thereto.

Similarly, the therapeutic use, method for treating and pharmaceutical composition for treatment all deliver the nitric oxide source to the pathogenic cells in the respiratory tract of the animal. The therapeutic use, method and composition may be used or applied for the treatment of any animal, preferably a mammal, including a human. Further, as indicated, the nitric oxide source in these instances is also preferably nitric oxide *per se*, however, the nitric oxide source may be a compound, composition or substance producing nitric oxide within the respiratory tract. In either event, the nitric oxide similarly suppresses the pathogenic cells in the respiratory tract of the animal. This suppression of the pathogenic cells may result in either or both of an inhibitory effect on the cells and a cidal effect on the cells. However, preferably, the nitric oxide has a cidal effect on the pathogenic cells in the respiratory tract exposed thereto.

20

As well, the pathogenic cells in the respiratory tract of the animal may be treated by nitric oxide and the delivering step of the therapeutic method may be performed in any manner and by any mechanism, device or process for delivering the nitric oxide source, and thus nitric oxide, either directly or indirectly to the respiratory tract of the animal. In the preferred embodiments of these aspects of the invention, the nitric oxide source is delivered directly by the inhalation route to the respiratory tract of the animal, preferably by either the spontaneous breathing of the animal or by ventilated or assisted breathing.

Further, in the preferred embodiments of these aspects of the invention, the pathogenic cells in the respiratory tract of the animal are treated by, and the delivering step of the therapeutic method is comprised of, exposing the pathogenic cells to the nitric oxide source, and thus nitric oxide, either directly or indirectly. More preferably, the pathogenic cells are directly exposed to the nitric oxide. As a result,

where desired, the effect of the nitric oxide may be localized to those pathogenic cells which are directly exposed thereto within the respiratory tract of the animal.

In addition, in all aspects of the invention, an effective amount of the  
5 nitric oxide source is defined by the amount of the nitric oxide source required to produce the desired effect of the nitric oxide, either inhibitory or cidal, on the pathogenic cells. Thus, the effective amount of the nitric source will be dependent upon a number of factors including whether the nitric oxide source is nitric oxide *per se* or a nitric oxide producing compound, the desired effect of the nitric oxide on the pathogenic cells and  
10 the manner in which the pathogenic cells are exposed to or contacted with the nitric oxide. In the preferred embodiments of the various aspects of the invention, the effective amount of the nitric oxide source is the amount of nitric oxide required to have a cidal effect on the pathogenic cells exposed directly thereto. Thus, the effective amount for any particular pathogenic cells will depend upon the nature of the pathogenic cells and  
15 can be determined by standard clinical techniques. Further, the effective amount will also be dependent upon the concentration of the nitric oxide to which the pathogenic cells are exposed and the time period or duration of the exposure.

Preferably, the pathogenic cells are exposed to a gas or a gas is delivered  
20 to the respiratory tract of the animal being treated, wherein the gas is comprised of the nitric oxide source. More preferably, the pathogenic cells are exposed to a gas comprised of nitric oxide. For instance, the gas may be comprised of oxygen and nitric oxide for delivery by the inhalation route to the respiratory tract of the animal being treated.

25 Although in the preferred embodiments of the various aspects of the invention, any effective amount of nitric oxide may be used, the concentration of the nitric oxide in the gas is preferably at least about 25 parts per million. Further, the concentration of the nitric oxide in the gas is preferably less than about 100 parts per million. Most preferably, the concentration of the nitric oxide in the gas is between  
30 about 25 and 90 parts per million.

Although the pathogenic cells may be exposed to the gas for any time period or duration necessary to achieve the desired effect, the pathogenic cells are preferably exposed to the gas, or the gas is delivered to the respiratory tract of the

animal, for a time period of at least about 3 hours. In the preferred embodiments of the various aspects of the invention, the pathogenic cells are exposed to the gas, or the gas is delivered to the respiratory tract of the animal, for a time period of between about 3 and 48 hours.

5

Finally, in the fourth embodiment of the invention, the apparatus or device is preferably comprised of a portable battery-operated, self-contained medical device that generates its own nitric oxide source, preferably nitric oxide gas, as a primary supply of nitric oxide. Further, the device may also include a conventional compressed gas supply of the nitric oxide source, preferably nitric oxide gas, as a secondary back-up system or secondary supply of nitric oxide.

Further, the device preferably operates to deliver nitric oxide in the gaseous phase to spontaneously breathing or to ventilated individual patients having microbial infections, by way of a specially designed nasal-cannula or a mask having a modified Fruman valve. In the preferred embodiment, nitric oxide gas is produced in cartridges through thermal-chemical, ultrasonic and/or electrochemical reaction and is released upon user inspiratory demand in pulsed-dose or continuous flow.

## 20 BRIEF DESCRIPTION OF THE DRAWINGS

The nature and scope of the invention will be elaborated in the detailed description which follows, in connection with the enclosed drawing figures, in which:

25 Figure 1 illustrates an airtight chamber for exposure of mycobacteria to varying concentrations of nitric oxide (NO) in tests of in vitro measurements of the cidal effects of exogenous NO;

Figure 2 is a graphical representation of experimental data showing the relationship of percent kill of microbes to exposure time for fixed doses of NO;

30 Figure 3a shows the external features of a pulse-dose delivery device for nitric oxide according to the present invention;

Figure 3b illustrates schematically the internal working components of the device of Figure 3a;

Figure 4 is a schematic illustration of the specialized valve used to control the delivery of nitric oxide in a preset dosage through the disposable nasal cannula of a device according to the present invention; and

Figure 5 is a schematic drawing of the mask-valve arrangement of a pulsed-dose nitric oxide delivery device according to the present invention.

10

#### DETAILED DESCRIPTION OF THE INVENTION

Studies of the Applicant on the exposure of extra cellular M. tuberculosis to low concentrations of NO for short periods have led to the conclusion that exogenous NO exerts a powerful dose-dependent and time-dependent mycobacteriocidal action. Further, it may be inferred that the large population of extracellular bacilli in patients with cavitary pulmonary tuberculosis are also vulnerable to exogenous (inhaled) NO.

#### Measurements of Cidal Activity of Exogenous NO

20

Referring to Figure 1, to re-create a normal incubation environment that allowed for the exposure of mycobacteria to varying concentrations of NO, an airtight "exposure chamber" (20) was built that could be seated in a heated biological safety cabinet (22). This chamber (20) measured 31 x 31 x 21 cm and is made of plexiglass. It has a lid (24) which can be firmly sealed, a single entry port (26) and a single exit port (28) through which continuous, low-flow, 5-10% CO<sub>2</sub> in air can pass, and a thermometer (30). A "Y" connector (32) in the inflow tubing allows delivery of NO, at predetermined concentrations, to the exposure chamber (20). Between the "Y" connector (32) and the exposure chamber (20) is a baffle box (34) which mixes the gases. Finally between the baffle box (34) and the exposure chamber (20) is placed an in-line NO analyzer (36), preferably a Pulmonox® Sensor manufactured by Pulmonox Medical Corporation, Tofield, Alberta, Canada. This analyzer (36) continuously measures NO concentration in the gas mixture entering the exposure chamber (20).

The day before conducting the experiments, a precise quantity of actively growing virulent *M. tuberculosis* was plated on solid media (38) (Middlebrook 7H-10 with OADC enrichment) after careful dilution using McFarland nephelometry (1 in 10 dilution, diluted further to an estimated  $10^3$  bacteria/ml and using a 0.1 ml inoculate of this suspension) (see Reference No. 11 above under the Background of the Invention). Control and test plates were prepared for each experiment. Control plates were placed in a CO<sub>2</sub> incubator (Forma Scientific, Marietta, Ohio) and incubated in standard fashion at 37 °C in 5-10% CO<sub>2</sub> in air.

Test plates were placed in the exposure chamber (20) for a pre-determined period of time after which they were removed and placed in the incubator along with the control plates. The temperature of the exposure chamber (20) was maintained at 32-34 °C. Colony counts were measured on control and test plates at 2, 3 and 6 weeks from the day of plating. Reported counts are those measured at three weeks expressed as a percentage of control.

Experiments were of two varieties: (1) those that involved exposure of the drug susceptible laboratory strain H37RV to fixed concentrations of NO, i.e. 0 (sham), 25, 50, 70 and 90 PPM for periods of 3, 6, 12, and 24 hours; and (2) those that involved exposure of a multidrug-resistant (isoniazid and rifampin) wild strain of *M. tuberculosis* to fixed concentrations of NO, i.e. 70 and 90 PPM for periods of 3, 6, 12 and 24 hours. One experiment at 90 PPM NO, that used both strains of *M. tuberculosis*, was extended to allow for a total exposure time of 48 hours. The NO analyzer (36) was calibrated at least every third experiment with oxygen (0 PPM of NO) and NO at 83 PPM.

#### Statistical Analysis

For each NO exposure time and NO concentration studied at least two, and in most cases three or four, separate experiments were performed with 3-6 exposure plates (38) per set. Colony counts performed on each exposure plate (38) were expressed as a percentage of the mean colony count of the matched non-exposed control plates. The values from all experiments at each NO concentration and exposure time were then averaged. These data were analyzed using two-way analysis of variance using the F



statistic to test for independent effects of NO exposure time and NO concentration and of any interaction between them on the colony counts.

### Experimental Results

5

A diagram of the incubation environment is shown in Figure 1. This environment exactly simulated the usual incubation environment of *M. tuberculosis* in the laboratory, with the following exceptions: (1) the temperature of our exposure chamber (20) was maintained at 32-34°C rather than the usual 37°C to avoid desiccation of the nutrient media upon which the bacteria were plated; and (2) the test plates were openly exposed. That a stable and comparable incubation environment was reproduced was verified in four sham experiments using the H37RV laboratory strain of *M. tuberculosis*. Colony counts on plates (38) exposed to 5-10% CO<sub>2</sub> in air (0 PPM NO) at 32-34°C in the exposure chamber (20) were not significantly different from those on control plates placed in the laboratory CO<sub>2</sub> incubator at 37°C, as shown in Table 1, below:

<b>TABLE 1</b> COLONY COUNTS AFTER EXPOSURE OF THE LABORATORY STRAIN (H37RV) OF <i>M. TUBERCULOSIS</i> TO VARYING CONCENTRATIONS OF NITRIC OXIDE FOR PERIODS OF 3, 6, 12 AND 24 HOURS				
Colony Counts (Mean ± SE) (expressed as percentage of control)				
NO (PPM)	Exposure Time (Hours)			
	3	6	12	24
0	107±5(6)*	100±5(6)	97±9(6)	105±5(18)
25	09±6(12)	109±4(12)	102±3(12)	66±4(18)
50	97 ± 5 (12)	96 ± 2 (12)	69 ± 3 (12)	41 ± 5 (18)
70	80 ± 10(7)	63 ± 12(7)	58 ± 12(11)	21 ± 6(11)
90	101 ± 15(11)	67 ± 7(11)	64 ± 7 (14)	15 ± 3(15)
* Numbers in brackets refer to the number of plates prepared for each NO concentration at each time interval.				

Seventeen experiments of the first variety, where plates (38) inoculated with a 0.1 ml suspension of  $10^3$  bacteria/ml of the H37RV strain of *M. tuberculosis* were exposed to a fixed concentration (either 0, 25, 50, 70 or 90 PPM) of NO for increasing periods of time (3, 6, 12 and 24 hours) were performed. The results have been pooled and are outlined in Table 1. There were both dose and time dependent cidal effects of NO that were very significant by two-way ANOVA (F ratio 13.4,  $P < .001$ ; F ratio 98.1,  $P < 0.0001$  respectively) and there was also a statistically significant interactive effect on microbial killing efficacy (F ratio 2.03,  $P < .048$ ). Although there was some variability in the percentage killed from experiment to experiment, increasing the standard error of the pooled data, the dose and time effect were highly reproducible. Only one control and one test (12 hour) plate at 90 PPM were contaminated. That the effect of NO was cidal and not inhibitory was confirmed by the absence of new colony formation beyond three weeks.

As described in Figure 2, the response to a fixed dose of NO was relatively linear with the slope of the line relating exposure time to percent kill increasing proportionally with the dose. Dose-related microbial killing did not appear to increase above 70 PPM NO, since colony counts at 70 and 90 PPM were indistinguishable. At 24 hours of NO exposure at both the 70 and 90 PPM NO levels, more than one third of the exposed plates were sterile. One experiment at 90 PPM NO was extended to allow for a total exposure time of 48 hours; all of these plates were sterile (see Figure 2 and Table 2 below)

<b>TABLE 2</b> COLONY COUNTS AFTER EXPOSURE OF A MULTIDRUG-RESISTANT WILD STRAIN OF <i>M. TUBERCULOSIS</i> TO NITRIC OXIDE FOR PERIODS OF 3, 6, 12, 24 AND 48 HOURS	
Colony Counts (Mean $\pm$ SE) (expressed as percentage of control)	

NO (PPM)	Exposure Time (Hours)				
	3	6	12	24	48
70	113 ± 2(4)	75 ± 4(4)	85 ± 10(4)	66 ± 4(4)	
			50 ± 25(4)	10 ± 5(4)	
90	97 ± 11(2)	91 ± 11(2)	71 ± 8(2)	36 ± 10(2)	
			59 ± 4(4)	32 ± 3(4)	0 ± 0(4)
			79 ± 5(4) <sup>#</sup>	20 ± 3(4) <sup>#</sup>	0 ± 0(4) <sup>#</sup>
<p>* Each series represents an individual experiment; numbers in brackets refer to the number of plates prepared for each experiment at each time interval.</p> <p><sup>#</sup> These results refer to the H37RV laboratory strain.</p>					

Four experiments of the second variety, where plates inoculated with a 0.1 ml suspension of 10<sup>3</sup> bacteria/ml of a multidrug-resistant wild strain of *M. tuberculosis*, were exposed to a fixed concentration (either 70 or 90 PPM) of NO for increasing periods of time (3, 6, 12 and 24 hours) were performed, two at each of 70 and 90 PPM NO. Again there was a significant dose and time dependent cidal effect (see Table 2 above). Although the percent kill at 24 hours was less than that observed with the H37RV strain, when an inoculum of this strain was exposed to 90 PPM NO for a period of 48 hours there was also 100% kill.

### Conclusion

Using an in vitro model in which the nitric oxide concentration of the incubation environment was varied, we have demonstrated that exogenous NO delivered at concentrations of less than 100 PPM exerts a powerful dose and time dependent mycobacteriocidal action. When an inoculate of *M. tuberculosis* that yielded countable colonies (0.1 ml of a suspension of 10<sup>3</sup> bacteria/ml) was plated on nutrient rich media and exposed to exogenous NO at 25, 50, 70 and 90 PPM for 24 hours there was approximately 30, 60, 80 and 85% kill, respectively. Similarly when plates of the same inocula were exposed to a fixed concentration of exogenous NO, for example 70 PPM, for increasing durations of time, the percentage of kill was directly proportional to exposure time; approximately 20, 35, 40 and 80% kill at 3, 6, 12 and 24 hours, respectively.

Of added interest, the dose and time dependent mycobacteriocidal effect of NO was similar for both the H37RV laboratory strain and a multidrug-resistant (isoniazid and rifampin) wild strain of *M. tuberculosis*, (after 24 and 48 hours exposure to 90 PPM NO, there was 85 and 100% kill and 66 and 100% kill of the two strains, respectively) expanding the potential therapeutic role of exogenous NO and suggesting that the mechanism of action of NO is independent of the pharmacologic action of these cidal drugs.

The dominant mechanism(s) whereby intracellular NO, known to be produced in response to stimulation of the calcium-independent inducible nitric oxide synthase, results in intracellular killing of mycobacteria is still unknown (see Reference No. 5 above under the Background of the Invention). Multiple molecular targets exist, including intracellular targets of peroxynitrite, the product of the reaction between NO and superoxide (see Reference No. 12 above under the Background of the Invention). Whatever the mechanism(s), there is evidence that NO may be active not just in murine but also in human alveolar macrophages (see References No. 6 - 9 above under the Background of the Invention), and furthermore that this activity may be critical to the mycobacteriocidal action of activated macrophages. Whether macrophase inducible NOS produces NO that has extracellular activity is not known but it is reasonable to expect that a measure of positive (mycobacteriocidal) and negative (tissue necrosis) activity might follow the death of the macrophase itself.

The relative ease with which NO may be delivered exogenously, and its theoretical ability to rapidly destroy the extracellular population of bacilli in the patient with sputum smear positive pulmonary tuberculosis, especially drug-resistant disease, have great clinical appeal.

### Primary Unit of the NO Post-Delivery Device

Referring to Figures 3a and 3b, the main unit (40) provides a small enclosure designed to hang on a belt. An A/C inlet (42) provides an electrical port to provide power to an internal rechargeable battery which powers the unit (40) if required. The user interface provides a multi-character display screen (44) for easy input and readability. A front overlay (46) with tactile electronic switches allows easy input from user to respond to software driven menu commands. LED and audible alarms (48) provide notification to user of battery life and usage. A Leur-type lock connector (50) or delivery outlet establishes communication with the delivery line to either the nasal cannula device (52) shown in Figure 4 or the inlet conduit on the modified Fruman valve (54) shown in Figure 5.

More particularly, referring to Figure 3b, the main unit (40) houses several main components. A first component or subassembly is comprised of an electronic/control portion of the device. It includes a microprocessor driven proportional valve or valve system (56), an alarm system, an electronic surveillance system and data input/output display system and electronic/software watch dog unit (44).

A second component or subassembly includes one or more disposable nitric oxide substrate cartridges (58) and an interface mechanism. A substrate converter system or segment (60) processes the primary compounds and converts it into pure nitric oxide gas. The gas then flows into an accumulator stable (62) and is regulated by the proportional valve assembly (56) into a NO outlet nipple (64).

A third component or subassembly is comprised of a secondary or backup nitric oxide system (66). It consists of mini-cylinders of high nitric oxide concentration under low-pressure. This system (66) is activated if and when the primary nitric oxide source (58) is found faulty, depleted or not available.

## Nasal Cannula Adjunct

Referring to Figure 4, there is shown a detailed drawing of a preferred embodiment of a valve (68) used to control the delivery of nitric oxide in a preset dosage through a disposable nasal cannula device (52) as shown. The valve (68) is controlled by the natural action of spontaneous respiration by the patient and the dosage is preset by the physical configuration of the device (52).

The device (52) including the valve (68) is constructed of dual lumen tubing (70). The internal diameter of the tubing (70) depends on the required dosage. The tubing (70) is constructed of material compatible with dry nitric oxide gas for the duration of the prescribed therapy. This tubing (70) is glued into the nasal cannula port (72).

The valve (68) is preferably comprised of a flexible flapper (74) that is attached by any mechanism, preferably a spot of adhesive (76), so as to be positioned over the supply tube (70). The flapper (74) must be sufficiently flexible to permit the valve action to be effected by the natural respiration of the patient. When the patient breathes in, the lower pressure in the nasal cannula device (52) causes the flapper (74) of the valve (68) to open and the dry gas is delivered from a reservoir (78) past the flapper (74) and into the patient's respiratory tract. When the patient exhales, positive pressure in the nasal cannula device (52) forces the flapper (74) of the valve (68) closed preventing any delivered gas entering the respiratory tract.

The supplied gas is delivered at a constant rate through the supply tube (70). The rate must be above that required to deliver the necessary concentration to the patient by filling the supply reservoir (78) up to an exhaust port (80) in the supply tube (70) during expiration. When the patient is exhaling the flapper (74) is closed and the supply gas feeds from a supply line (82) through a cross port (84) into the reservoir or storage chamber (78). The length of the reservoir chamber (78) given as dimension (86) determines the volume of gas delivered when the patient inhales. Inhaling opens the flapper (74) of the valve (68) and causes the reservoir chamber (78) to be emptied.

During exhalation when the flapper (74) is closed and the reservoir chamber (78) is filling, any excess gas exhausts through the exhaust port (80). During inhalation when the reservoir chamber (78) is emptied, the reservoir chamber (78) is displaced with atmospheric air through the exhaust port (80). There will continue to be supply gas from the supply line (82) through the cross port (84) during inhalation and this amount must be figured into the total delivered gas to determine the actual dosage. The tubing lumens (70) include various plugs (88) to direct the flow.

#### Mask/Valve Adjunct

10

Referring to Figure 5, there is shown a further embodiment of a nitric oxide valve (54) which is a modification and improvement of a Non-rebreathing valve for gas administration, referred to as a "Modified Fruman Valve," as shown and particularly described in United States of America Patent No. 3,036,584 issued May 29, 1962 to Lee.

15

More particularly, the within invention specifically redesigns the Modified Fruman Valve for use in inhaled nitric oxide therapy. Specifically, in the preferred embodiment shown in Figure 5, one end of a valve body (90) or valve body chamber is comprised of or includes a mask or mouth-piece (not shown) attached thereto. The connection is preferably standardized to a 22 mm O.D. to facilitate the attachment of the mask or mouth-piece. The other end of the valve body (90) is comprised of or provides an exhaust port (92). The exhaust port (92) entrains ambient air during the latter portion of inspiration and dilutes the nitric oxide coming from an inlet conduit (94).

20  
25

The resultant nitric oxide concentration in the valve body (90) is determined by the dilutional factors regulated by the valve (54), tidal volume and the nitric oxide concentration in an attached flexed bag (96), being a fixed reservoir bag. The inlet conduit (94) is preferably spliced for the attachment of the small flexed bag (96). The purpose of the bag (96) is to act as a reservoir for nitric oxide gas. Further, an opening of the inlet conduit (94) is preferably modified to facilitate the attachment or connection of the inlet conduit (94) to a supply hose emanating from a nitric oxide

30

supply chamber. Specifically, the opening of the inlet conduit (94) is preferably comprised of a knurled hose barb connector (98)



The embodiments of the invention in which an exclusive privilege or property is claimed are defined as follows:

1. A method for suppressing pathogenic cells comprising the step of exposing the pathogenic cells to an effective amount of a nitric oxide source.
2. The method as claimed in claim 1 wherein the pathogenic cells are pathogenic microorganisms.
3. The method as claimed in claim 2 wherein the microorganisms are selected from the group comprised of pathogenic bacteria, pathogenic parasites and pathogenic fungi.
4. The method as claimed in claim 3 wherein the microorganisms are pathogenic mycobacteria.
5. The method as claimed in claim 4 wherein the pathogenic mycobacteria is *M. tuberculosis*.
6. The method as claimed in claim 1, 2, 3, 4 or 5 wherein the nitric oxide source is nitric oxide.
7. The method as claimed in claim 6 wherein the exposing step is comprised of directly exposing the pathogenic cells to the nitric oxide.
8. The method as claimed in claim 7 wherein the nitric oxide has a cidal effect on the pathogenic cells.
9. The method as claimed in claim 8 wherein the exposing step is comprised of exposing the pathogenic cells to a gas comprised of the nitric oxide and wherein the concentration of the nitric oxide in the gas is at least about 25 parts per million.
10. The method as claimed in claim 8 wherein the exposing step is comprised of exposing the pathogenic cells to a gas comprised of the nitric oxide and wherein the concentration of the nitric oxide in the gas is less than about 100 parts per million.

11. The method as claimed in claim 10 wherein the concentration of the nitric oxide in the gas is between about 25 and 90 parts per million.
- 5 12. The method as claimed in claim 9, 10 or 11 wherein the pathogenic cells are exposed to the gas for a time period of at least about 3 hours.
13. The method as claimed in claim 12 wherein the pathogenic cells are exposed to the gas for a time period of between about 3 and 48 hours.
- 10 14. A method for treating an animal having pathogenic cells in the respiratory tract of the animal comprising the step of delivering by the inhalation route to the respiratory tract of the animal an effective amount of a nitric oxide source.
- 15 15. The method as claimed in claim 15 wherein the pathogenic cells are pathogenic microorganisms.
16. The method as claimed in claim 15 wherein the microorganisms are selected from the group comprised of pathogenic bacteria, pathogenic parasites and pathogenic  
20 fungi.
17. The method as claimed in claim 16 wherein the microorganisms are pathogenic mycobacteria.
- 25 18. The method as claimed in claim 17 wherein the pathogenic mycobacteria is *M. tuberculosis*.
19. The method as claimed in claim 14, 15, 16, 17 or 18 wherein the nitric oxide source is nitric oxide.
- 30 20. The method as claimed in claim 19 wherein the animal is a human.

21. The method as claimed in claim 19 wherein the delivering step is comprised of directly exposing the pathogenic cells in the respiratory tract of the animal to the nitric oxide.
- 5 22. The method as claimed in claim 21 wherein the nitric oxide has a cidal effect on the pathogenic cells.
23. The method as claimed in claim 22 wherein the animal is a human.
- 10 24. The method as claimed in claim 22 wherein the delivering step is comprised of delivering a gas comprised of the nitric oxide by the inhalation route to the respiratory tract of the animal and wherein the concentration of the nitric oxide in the gas is at least about 25 parts per million.
- 15 25. The method as claimed in claim 22 wherein the delivering step is comprised of delivering a gas comprised of the nitric oxide by the inhalation route to the respiratory tract of the animal and wherein the concentration of the nitric oxide in the gas is less than about 100 parts per million.
- 20 26. The method as claimed in claim 25 wherein the concentration of the nitric oxide in the gas is between about 25 and 90 parts per million.
27. The method as claimed in claim 24, 25 or 26 wherein the animal is a human.
- 25 28. The method as claimed in claim 24, 25 or 26 wherein the gas is delivered to the respiratory tract of the animal for a time period of at least about 3 hours.
29. The method as claimed in claim 28 wherein the gas is delivered to the respiratory tract of the animal for a time period of between about 3 and 48 hours.
- 30 30. The method as claimed in claim 29 wherein the animal is a human.
31. The use of an effective amount of a nitric oxide source for suppressing pathogenic cells exposed thereto.

32. The use as claimed in claim 31 wherein the pathogenic cells are pathogenic microorganisms.
- 5 33. The use as claimed in claim 32 wherein the microorganisms are selected from the group comprised of pathogenic bacteria, pathogenic parasites and pathogenic fungi.
34. The use as claimed in claim 33 wherein the microorganisms are pathogenic mycobacteria.
- 10 35. The use as claimed in claim 34 wherein the pathogenic mycobacteria is *M. tuberculosis*.
- 15 36. The use as claimed in claim 31, 32, 33, 34 or 35 wherein the nitric oxide source is nitric oxide.
37. The use as claimed in claim 36 wherein the pathogenic cells are directly exposed to the nitric oxide.
- 20 38. The use as claimed in claim 37 wherein the nitric oxide source has a cidal effect on the pathogenic cells directly exposed thereto.
39. The use as claimed in claim 38 comprising the use of a gas comprised of the nitric oxide, wherein the concentration of the nitric oxide in the gas is at least about 25 parts per million.
- 25 40. The use as claimed in claim 38 comprising the use of a gas comprised of the nitric oxide, wherein the concentration of the nitric oxide in the gas is less than about 100 parts per million.
- 30 41. The use as claimed in claim 40 wherein the concentration of the nitric oxide in the gas is between about 25 and 90 parts per million.

42. The therapeutic use of an effective amount of a nitric oxide source for the treatment by the inhalation route of an animal having pathogenic cells in the respiratory tract of the animal.
- 5 43. The therapeutic use as claimed in claim 42 wherein the pathogenic cells are pathogenic microorganisms.
44. The therapeutic use as claimed in claim 43 wherein the microorganisms are selected from the group comprised of pathogenic bacteria, pathogenic parasites and  
10 pathogenic fungi.
45. The therapeutic use as claimed in claim 44 wherein the microorganisms are pathogenic mycobacteria.
- 15 46. The therapeutic use as claimed in claim 45 wherein the pathogenic mycobacteria is *M. tuberculosis*.
47. The therapeutic use as claimed in claim 42, 43, 44, 45 or 46 wherein the nitric oxide source is nitric oxide.  
20
48. The therapeutic use as claimed in claim 47 wherein the animal is a human.
49. The therapeutic use as claimed in claim 47 wherein the pathogenic cells in the respiratory tract of the animal are directly exposed to the nitric oxide.  
25
50. The therapeutic use as claimed in claim 49 wherein the nitric oxide has a cidal effect on the pathogenic cells directly exposed thereto.
51. The therapeutic use as claimed in claim 50 wherein the animal is a human.  
30
52. The therapeutic use as claimed in claim 50 comprising the use of a gas comprised of the nitric oxide, wherein the concentration of the nitric oxide in the gas is at least about 25 parts per million.

53. The therapeutic use as claimed in claim 50 comprising the use of a gas comprised of the nitric oxide, wherein the concentration of the nitric oxide in the gas is less than about 100 parts per million.

5 54. The therapeutic use as claimed in claim 53 wherein the concentration of the nitric oxide in the gas is between about 25 and 90 parts per million.

55. The therapeutic use as claimed in claim 52, 53 or 54 wherein the animal is a human.

10

56. A pharmaceutical composition for use in the treatment by the inhalation route of an animal having pathogenic cells in the respiratory tract of the animal, the pharmaceutical composition comprising an effective amount of a nitric oxide source.

15 57. The composition as claimed in claim 56 wherein the pathogenic cells are pathogenic microorganisms.

58. The composition as claimed in claim 57 wherein the microorganisms are selected from the group comprised of pathogenic bacteria, pathogenic parasites and pathogenic  
20 fungi.

59. The composition as claimed in claim 58 wherein the microorganisms are pathogenic mycobacteria.

25 60. The composition as claimed in claim 59 wherein the pathogenic mycobacteria is *M. tuberculosis*.

61. The composition as claimed in claim 56, 57, 58, 59 or 60 wherein the nitric oxide source is nitric oxide.

30

62. The composition as claimed in claim 61 wherein the animal is a human.

63. The composition as claimed in claim 61 wherein the pathogenic cells in the respiratory tract of the animal are directly exposed to the nitric oxide.


64. The composition as claimed in claim 63 wherein the nitric oxide has a cidal effect on the pathogenic cells directly exposed thereto.
- 5 65. The composition as claimed in claim 64 wherein the animal is a human.
66. The composition as claimed in claim 64 comprising a gas comprised of the nitric oxide, wherein the concentration of the nitric oxide in the gas is at least about 25 parts per million.
- 10 67. The composition as claimed in claim 64 comprising a gas comprised of the nitric oxide, wherein the concentration of the nitric oxide in the gas is less than about 100 parts per million.
- 15 68. The composition as claimed in claim 67 wherein the concentration of the nitric oxide in the gas is between about 25 and 90 parts per million.
69. The composition as claimed in claim 66, 67 or 68 wherein the animal is a human.


## ABSTRACT OF INVENTION


The invention relates to a method for suppressing pathogenic cells and a method for the treatment of an animal, including a human, having pathogenic cells within its respiratory tract. These methods preferably comprise the exposure of the pathogenic cells to an effective amount of a source of nitric oxide, the nitric oxide source comprising nitric oxide or a compound or substance capable of producing nitric oxide and wherein the nitric oxide may have either an inhibitory or a cidal effect on such pathogenic cells. Further, the invention relates to the use of nitric oxide for suppressing pathogenic cells, the therapeutic use of nitric oxide for the treatment of an animal having pathogenic cells in its respiratory tract and a pharmaceutical composition for such treatment.



Figure 1







**Figure 3a**

Figure 3b






Figure 4





**Figure 5**